descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 1984 English Publisher:Elsevier BVJournal:Clinical Neurology and Neurosurgery, volume 86, pages 172-177 (issn: 0303-8467,

Authors: D.B. Calne; K. Burton;

doi: 10.1016/0303-8467(84)90194-x

pmid: 6091965

Dopamine agonists and Parkinson's disease

- Summary
- Subjects
- Metrics

Abstract

The therapeutic use of dopamine agonists for Parkinson's disease, clinical guidelines for their introduction into antiparkinson regimens, and their range of adverse effects are reviewed. The role played by the dopaminomimetic ergots in elucidating dopamine receptor function, and laboratory methods that identify dopamine agonists, are also examined.

Related Organizations

University of British Columbia
Canada

Keywords

Neurons, Ergot Alkaloids, Apomorphine, Brain, Parkinson Disease, Receptors, Dopamine, Antiparkinson Agents, Levodopa, Piribedil, Humans, Ergolines, Lisuride, Bromocriptine, Pergolide

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	7
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average